Remove Drugs Remove Process Chemistry Remove Treatment
article thumbnail

Macrocyclization via Ring-Closing Metathesis in Drug Discovery & Process Chemistry

Drug Hunter

Macrocyclic molecules, containing 12 or more atoms in a ring system, are increasingly prevalent in drug discovery, with over 67 macrocyclic drugs approved so far and several notable examples of clinical success highlighted on Drug Hunter recently, including MK-0616 , repotrectinib , and pacritinib.

article thumbnail

Metabolism of macrocyclic drugs

Metabolite Tales Blog

Metabolism of de novo-designed macrocyclic drugs approved by the FDA By Julia Shanu-Wilson To date, only 4% (67) of FDA approved drugs are macrocycles [1]. However, in the quest to tackle challenging disease targets with difficult drug binding sites, there is revived interest in developing this compound type to offer unique solutions.

Drugs 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Welcome to new Director David Hulcoop

The Open Targets Blog

I then moved back to the UK to work as a process chemist at GSK, designing the manufacturing routes for small molecule drugs. This involves scaling up the process of making a few grams of the compound in the lab to hundreds of tonnes in a factory, in an environmentally-friendly, cost-effective way.

article thumbnail

Metabolism of de novo designed macrocyclic drugs

Metabolite Tales Blog

Metabolism of de novo-designed macrocyclic drugs approved by the FDA By Julia Shanu-Wilson To date, only 4% (67) of FDA approved drugs are macrocycles [1]. However, in the quest to tackle challenging disease targets with difficult drug binding sites, there is revived interest in developing this compound type to offer unique solutions.

Drugs 52
article thumbnail

Empowering women in STEM: Navigating CMC regulatory affairs

Drug Target Review

Dr Lopa Bakrania brings over 18 years of experience in pharmaceutical process chemistry and CMC regulatory affairs. Throughout her career, Bakrania has held pivotal roles at renowned companies, including Biohaven, where she contributed to the development of therapies, such as migraine treatment Nurtec ODT.

Science 59